{
    "nctId": "NCT01821833",
    "briefTitle": "Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel",
    "officialTitle": "A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Ovarian Neoplasm, Pain",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Mean severity of pain",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients have a diagnosis of breast cancer or ovarian cancer\n* Patients are scheduled to receive weekly paclitaxel at 70-90 mg/m\\^2 for a minimum of 2 months; 3 out of 4 weeks is allowed\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2\n* Patients must not have taken omega-3-fatty acid supplements within the past 1 month prior to registration and must agree to refrain from use of omega- 3 fatty acid supplements from sources outside the study\n* Patients must not be on nonsteroidal anti-inflammatory drugs (NSAIDS) or aspirin for at least 1 week prior to registration; NSAIDS or aspirin are allowed after enrollment\n* Patients must not have received any other analgesics (opiates and tramadol) 1 week prior to registration; analgesics (opiates and tramadol) are allowed after enrollment\n* Patients must have the ability to complete questionnaires by themselves or with assistance\n* Patients must not be on anticoagulation medication (heparin/ warfarin) within 28 days prior to registration, because of increased risk of bleeding\n* Concurrent treatment with carboplatin +/- bevacizumab is allowed\n* Concurrent treatment with human epidermal growth factor receptor (Her2 neu) targeted therapy is allowed\n\nExclusion Criteria:\n\n* Known allergy to omega 3 fatty acids, fish or shellfish\n* Pre-existing diagnosis of peripheral neuropathy\n* Diagnosis of fibromyalgia\n* Concurrent planned neutrophil colony stimulating factor therapy\n* Prior exposure to paclitaxel within the last 6 months",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}